Overview

A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia

Status:
RECRUITING
Trial end date:
2029-10-01
Target enrollment:
Participant gender:
Summary
To learn the recommended dose of momelotinib that can be given in combination with gilteritinib to participants with AML.
Phase:
PHASE1
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
GlaxoSmithKline
Treatments:
gilteritinib
N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide